(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities in the omics-based clinical trials sector include the rising adoption of personalized medicine, advancements in genomic technologies, integration of AI, and innovation in bioinformatics. Expansion is driven by increasing prevalence of chronic diseases and demand for precision therapies, especially in Asia-Pacific.

Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Omics-Based Clinical Trials Market Report 2025" has been added to ResearchAndMarkets's offering.

The Omics-Based Clinical Trials Global Market Report 2025 equips strategists, marketers, and senior management with essential insights necessary to evaluate the market. This comprehensive report focuses on the rapidly expanding omics-based clinical trials sector, offering a roadmap to the prevailing trends that will shape this industry in the upcoming decade and beyond.

The omics-based clinical trials market is undergoing rapid expansion, with its market size predicted to grow from $29.1 billion in 2024 to $31.71 billion in 2025, marking a robust CAGR of 8.9%. This growth is driven by an increasing number of clinical trials incorporating omics technologies, heightened focus on translational research, rising government investments, and greater availability of biobanks.

Forecasts suggest that by 2029, the market will reach $44.08 billion, propelled by a CAGR of 8.6%. Key factors include the rising demand for personalized medicine, broader adoption of multi-omics methodologies, and expanding investment in genomic research. Rapid advancements in next-generation sequencing (NGS), AI integration with omics platforms, and novel bioinformatics tools further contribute to this growth.

Personalized medicine, characterized by tailoring medical treatment to individual characteristics, stands as a major growth driver for this sector. This approach has gained traction due to significant advances in genomic technologies enabling comprehensive genetic profiling. Omics-based clinical trials enhance personalized treatment strategies by evaluating patients' genetic, proteomic, and metabolic profiles for more effective interventions. In 2022, 34% of newly approved therapies by the Personalized Medicine Coalition were personalized medicines, reinforcing the trend's upward trajectory.

Innovations such as HiFi sequencing technology are revolutionizing data analysis in clinical trials, improving trial outcomes. For instance, in October 2024, Pacific Biosciences, in partnership with A\STAR and Macrogen Inc., established a cutting-edge genomics lab in Singapore, utilizing advanced long-read sequencing for comprehensive genomic studies.

The strategic acquisition by Bruker Corporation of Biocrates Life Sciences AG in June 2025 exemplifies industry consolidation aimed at enhancing multi-omics capabilities. This acquisition enables integration of metabolomics technologies, delivering robust workflows for clinical research.

Prominent entities in this market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and BioNTech SE among others. North America leads the market with the Asia-Pacific region poised for the fastest growth, covering key markets like the USA, China, India, and the UK. However, the sector faces challenges due to global trade tensions affecting the supply and pricing of medical devices and pharmaceuticals, urging companies to diversify supply chains and seek local manufacturing solutions.

Omics-based clinical trials embrace genomics, proteomics, transcriptomics, metabolomics, and epigenomics to explore disease mechanisms and tailor medical care, significantly impacting areas such as oncology, cardiovascular medicine, and rare disease diagnosis. These trials leverage high-throughput molecular data to enhance patient selection, therapy optimization, and biomarker discovery.

This market research report offers a comprehensive analysis of the omics-based clinical trials industry, providing insights into market trends, opportunities, segment details, and competitive landscapes. It includes detailed revenue assessments and projections for various geographical regions, supporting stakeholders in strategic planning and decision-making.

Key Attributes:

Report Attribute	Details
No. of Pages	250
Forecast Period	2025 - 2029
Estimated Market Value (USD) in 2025	$31.71 Billion
Forecasted Market Value (USD) by 2029	$44.08 Billion
Compound Annual Growth Rate	8.6%
Regions Covered	Global

Reasons to Purchase:

• Obtain a comprehensive global perspective with the most exhaustive report available, covering 15 different geographies.
• Analyze the influence of pivotal macro factors such as geopolitical conflicts, trade policies, pandemic-induced supply chain adjustments, inflation, interest rate variations, and regulatory changes.
• Formulate regional and national strategies based on localized data and analysis.
• Identify potential growth segments for investment.
• Outperform competitors using predictive data and market-driving factors.
• Enhance customer understanding based on the most current market shares.
• Benchmark against leading competitors.
• Support presentations with high-quality, reliable data and analysis.
• Receive the latest data updates in an Excel data sheet for seamless data extraction and analysis.
• Access the report data in an interactive Excel dashboard format.

Companies Featured

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Novo Nordisk A/S
• BioNTech SE
• IQVIA Inc.
• Laboratory Corporation of America Holdings
• ICON Public Limited Company
• SGS Societe Generale de Surveillance SA
• Eurofins Scientific SE
• Syneos Health Inc.
• Illumina Inc.
• Charles River Laboratories International Inc.
• Parexel International Corporation
• Bruker Corporation
• Fulgent Genetics Inc.
• Signios Biosciences
• BioAro Inc.

Scope:

• Type: Genomics, Proteomics, Metabolomics, Transcriptomics
• Phase: Phase I, Phase II, Phase III, Phase IV
• Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
• Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders
• End-User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Hospitals and Diagnostic Laboratories

Subsegments:

• Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing
• Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping
• Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis
• Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Omics-Based Clinical Trials Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN04112025004107003653ID1110293628